Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy - Takeaways - MDSpire

Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy

  • By

  • Florien J. G. van Amstel

  • Rik G. M. van Mierlo

  • Patty J. Nelemans

  • Sanne M. E. Engelen

  • Janneke Houwers

  • Loes F. S. Kooreman

  • Vivianne C. G. Tjan-Heijnen

  • Sabine Siesling

  • Marjolein L. Smidt

  • Thiemo J. A. van Nijnatten

  • December 23, 2025

  • 0 min

Share

  • 1

    Neoadjuvant chemotherapy (NACT) is increasingly used in breast cancer treatment, shifting from adjuvant to preoperative settings.

  • 2

    Breast MRI is the most accurate method for monitoring primary tumour response during NACT, indicating potential surgical and prognostic benefits.

  • 3

    Breast radiologic complete response (rCR) on MRI is associated with improved pathologic outcomes, including ypT0 and ypN0 rates.

  • 4

    The study aims to assess whether breast MRI can predict axillary pathologic response in breast cancer patients treated with NACT.

  • 5

    Patient subgroups with high ypN0 probabilities may benefit from breast MRI assessments to guide de-escalation strategies in axillary treatment.

Original Source(s)

Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy

  • by Florien J. G. van Amstel, Rik G. M. van Mierlo, Patty J. Nelemans, Sanne M. E. Engelen, Janneke Houwers, Loes F. S. Kooreman, Vivianne C. G. Tjan-Heijnen, Sabine Siesling, Marjolein L. Smidt, Thiemo J. A. van Nijnatten

  • December 23, 2025

Related Content

Latent class analysis of conventional ultrasound features: a novel approach to predicting non-response to neoadjuvant chemotherapy in breast cancer

Dana-Farber Research News 03.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 - 28.

  • by

  • March 15, 2026

  • 21 min
Axillary response and diagnostic accuracy of imaging modalities after neoadjuvant chemotherapy for breast cancer (retrospective single center study)